Everything you need to know about human acellular dermal matrix (hADM), extracellular matrix (ECM) skin boosters, and why Re20 has become one of the most talked-about regenerative injectables in Korean — and Singaporean — dermatology.

Somewhere between the tenth cream that promised to restore your collagen and the fourth skin booster that delivered a beautiful glow that faded in six weeks, you may have started wondering whether any of these treatments actually address what is happening underneath. The honest answer, for most conventional injectables, is: not fully. They treat the symptoms of ageing — dryness, dullness, fine lines — without touching the root cause. The extracellular matrix.

The extracellular matrix, or ECM, is the three-dimensional structural framework that fills the space between every cell in your skin. It is made of collagen, elastin, hyaluronic acid, glycosaminoglycans, and structural proteins — and it is the reason youthful skin looks and behaves the way it does: firm, elastic, hydrated, resilient. When the ECM deteriorates with age, sun exposure, and chronic inflammation, the visible results are not just wrinkles or dryness. The entire architecture of the skin weakens. And no topical product, no matter how active its ingredients, can reach it.

ECM skin boosters — specifically, human acellular dermal matrix (hADM) injectables — represent one of the most significant shifts in skin rejuvenation science in a decade. Rather than asking the skin to rebuild itself from signals and scaffolds, they deliver the actual building materials of the ECM directly into the dermis. Re20, manufactured by L&C Bio in Seoul and now available at Ozhean Zoey Medical & Aesthetic Clinic, is the product that launched this category and currently leads it. This guide explains the science in full: what hADM is, where it comes from, what the ECM does, why Re20 became Korea's go-to skin booster in under twelve months, and what you should know before choosing an ECM skin booster for yourself.

Understanding the Extracellular Matrix: The Architecture Beneath Your Skin

Most people think of their skin as layers: surface skin, dermis, subcutaneous tissue. What this mental model misses is what lies between the cells in those layers — a living, dynamic three-dimensional network of structural proteins and carbohydrate chains that holds everything together, regulates cell behaviour, controls hydration, and determines how the skin responds to damage and age. That network is the extracellular matrix.

The ECM is not a passive filler. It is an active regulatory environment. Research published in the Journal of Dermatological Science demonstrates that ECM deterioration is a more central driver of visible skin ageing than individual collagen loss alone — because the ECM governs not just structural support but the behaviour of the fibroblasts that produce collagen and elastin. When the ECM is healthy, fibroblasts operate efficiently, laying down new collagen and maintaining dermal density. When the ECM is degraded — fragmented collagen networks, depleted elastin, reduced glycosaminoglycan content — fibroblasts lose their functional cues. They do not rebuild well because the environment that directs rebuilding is no longer intact.

The ECM is composed of several key components, each with a distinct function:

•     Collagen (approximately 80% of ECM dry weight) — the primary structural protein providing tensile strength and firmness. Type I collagen is the dominant form in adult dermis; Type III collagen is more abundant in younger skin and in healing tissue.
•     Elastin (~3%) — the protein responsible for skin's ability to stretch and recoil. Once lost in adulthood, elastin is extremely difficult to replace through conventional skin booster stimulation.
•     Glycosaminoglycans (GAGs) — long polysaccharide chains including hyaluronic acid, heparan sulphate, and dermatan sulphate. They attract and retain water within the matrix, providing hydration, cushioning, and growth factor binding capacity.
•     Structural proteins — including fibronectin and laminin, which anchor cells to the matrix and regulate cell migration, proliferation, and differentiation.

By the time visible ageing is apparent, the ECM has been deteriorating for years. Collagen content is reduced by approximately 1% per year after the age of twenty-five. Elastin is not regenerated in meaningful quantities after adolescence. GAG concentration declines steadily. The result is a dermis that is literally thinner, less supple, and less capable of supporting the surface skin above it — regardless of what you apply topically.

What Is hADM? How Human Acellular Dermal Matrix Is Derived

Human acellular dermal matrix (hADM) is the term for human dermal tissue that has been scientifically processed to remove all cellular components — every living cell, all DNA, all lipid residues, all immunogenic material — while preserving the three-dimensional protein architecture of the extracellular matrix intact.

The starting material is donated human dermal tissue, processed under strict regulatory frameworks in accredited tissue banks. The decellularisation process — the science of removing all cellular content without destroying the structural matrix — is technically demanding. It requires the removal of all cellular debris, membrane fragments, residual lipids, and surfactant residues from the processing chemistry, while leaving the collagen network, elastin fibres, glycosaminoglycan chains, and structural proteins undamaged and in their native spatial configuration.

The resulting hADM is a cell-free, structurally intact ECM scaffold. For surgical applications — burn reconstruction, hernia repair, breast reconstruction after mastectomy, periodontal surgery — this material has been used for over three decades and has an extensive published biocompatibility record. The innovation of the ECM skin booster category is taking this well-established surgical material, micronising it into particles small enough to pass through a fine-gauge injection needle, and delivering it intradermal for aesthetic skin restoration.

What is injected into the dermis during a Re20 session is therefore not a synthetic mimic of the ECM, not a growth factor signal, not a scaffold made of polymer — it is actual human ECM: the real structural proteins and carbohydrate chains that youthful skin is made of, purified to medical-grade standards and delivered directly to where the skin's own depleted matrix needs reinforcement.

Decellularisation: Why the Processing Method Matters

Not all hADM is processed equally. The quality of the final product depends entirely on the rigour and specificity of the decellularisation chemistry used by the manufacturer. Poor decellularisation leaves residual cellular debris, DNA fragments, and — critically — residual lipid membranes and surfactant compounds from the processing chemicals themselves.

Residual lipid matters because oxidised fatty acids and lipolytic metabolites are recognised by the innate immune system as damage signals. They activate macrophages and neutrophils, producing local inflammation at the injection site — swelling, induration, pain, and in rare cases, granulomatous reactions that can persist for months. Residual surfactants from the decellularisation process (particularly deoxycholic acid and sodium dodecyl sulphate) have direct cytotoxic effects on fibroblasts. In short, the purity of the hADM determines not just the safety of the injection but how well the delivered matrix integrates with the patient's own tissue and how effectively it supports fibroblast function.

Re20 is manufactured using L&C Bio's proprietary AlloClean decellularisation platform, which achieves a residual DNA content of less than 50 ng/mg — well within the internationally accepted threshold for acellular biologics — and a net ECM composition of approximately 80 per cent collagen, 3 per cent elastin, and 0.4 per cent sulphated GAGs. This compositional profile closely mirrors the natural ECM of healthy young adult dermis. L&C Bio holds AATB (American Association of Tissue Banks) establishment accreditation — the global standard for tissue banking quality systems — and its regulatory record across tissue product lines is, at time of writing, clean.

How ECM Skin Boosters Work Differently From Every Other Injectable

To appreciate what makes hADM skin boosters categorically different, it helps to understand what the other generations of skin boosters actually do — and where each one stops.

Generation 1: Hyaluronic Acid Skin Boosters

HA skin boosters deliver hydration rapidly and visibly. Hyaluronic acid holds up to a thousand times its weight in water, plumping the dermis, improving surface texture, and creating the dewy luminosity that makes patients look immediately more rested and radiant after treatment. The limitation is that HA does not structurally restore the dermis. The effect is temporary — typically three to six months — because injected HA is enzymatically degraded, and the underlying ECM deterioration that created the dryness and dullness has not been addressed. Hydration returns to baseline when the HA clears.

Generation 2: Polynucleotide (PN) Skin Boosters

PN injectables deliver DNA fragments that act as biological signalling molecules, stimulating fibroblast activity and reducing inflammatory cytokine expression in the dermis. They improve skin quality, reduce redness, support repair, and have particular value in inflamed or sensitised skin. What PN does not do is physically restore the ECM. It creates a healthy environment for fibroblasts but does not give them the structural material — the collagen, elastin, and GAG framework — they need to rebuild the matrix. Fibroblasts that receive PN signals in a degraded ECM environment are being asked to rebuild without raw materials.

Generation 3–4: Biostimulators (PDLLA, CaHA, PCL)

Biostimulators — whether poly-D,L-lactic acid, calcium hydroxylapatite, or polycaprolactone — stimulate robust collagen production by creating a temporary scaffold or inflammatory stimulus that the body responds to with new Type I collagen synthesis. These are powerful tools currently available for collagen regeneration in aesthetic medicine, and they produce visible structural improvement in firmness and contour. Their limitation is specificity: they primarily drive collagen synthesis. They do not restore elastin (near-impossible to regenerate in meaningful quantities in adult skin), they do not replenish GAGs with the structural spatial organisation of the native matrix, and they do not restore ECM architecture. They build more collagen inside a still-degraded ECM environment.

Generation 5: ECM Skin Boosters (hADM)

ECM skin boosters bypass all of the indirect signalling approaches and deliver the structural components of the matrix itself. When Re20 is injected into the mid-dermis, the micronised hADM particles integrate with the patient's own residual ECM and provide immediate structural support: real collagen fibres, real elastin chains, real GAGs in their native configuration. Simultaneously, the restored ECM environment provides fibroblasts with the spatial and biochemical cues they need to resume normal regenerative activity — producing their own collagen, elastin, and GAGs in response to a matrix that is no longer fragmented and degraded.

This dual mechanism — immediate structural support followed by sustained regenerative signalling — is what patients and clinicians observe as the characteristic Re20 result: initial improvement within the first one to two weeks as the ECM particles integrate, followed by progressive improvement over two to three months as fibroblast activity normalises. The skin does not just look refreshed. It starts to behave healthier too: more resilient, more hydrated from within, more responsive to other treatments performed alongside or after Re20.

Think of it this way. If the skin is a garden, conventional skin boosters water the plants, send growth signals, or plant synthetic seeds. Re20 replenishes the soil. And healthy soil changes everything the garden can produce.

Why Re20 Became Korea's Go-to Skin Booster in Under Twelve Months

Korea's aesthetic medicine market is ruthlessly selective. Treatments gain traction not because of marketing spend, but because dermatologists see consistent, differentiated clinical results and patients notice them. When Re20 launched in late 2024 through Elravie (a brand of L&C Bio), word spread through Korea's Gangnam clinic networks faster than any skin booster had in years. By mid-2025, "Re20" and "ECM skin booster" — 水光针 reimagined for the structural age — had become some of the most-searched aesthetic terms on Naver, Korea's dominant search engine.

The reason is results that are qualitatively different from what patients had seen before. HA boosters give hydration. PN gives repair. Biostimulators give firmness. Re20 gives all of these simultaneously — not because it is a combination product, but because the ECM governs all of these functions. When the matrix is restored, skin texture improves because the dermis is denser. Pores appear refined because better-supported tissue has more structural integrity. Radiance improves because hydration is retained more efficiently. Firmness increases as fibroblasts resume normal collagen synthesis in a restored matrix environment. The patients describing their results as "my skin just looks healthier everywhere" are not being imprecise — they are accurately describing what happens when the root cause of multiple skin quality concerns is addressed simultaneously.

The speed of adoption through Korea's most discerning clinics — institutions whose reputations rest on consistently delivering visible, natural, evidence-supported results — is, in itself, the strongest signal of Re20's clinical validity. This is a market where no product survives on marketing alone. By 2026, Re20 has spread from Gangnam to Busan, Daegu and beyond, and is now available at authorised clinics in Singapore, Japan (where it is marketed under the name BNAJU), and other Asian markets. In Singapore, Ozhean Zoey has been performing Re20 treatments since 2025 as part of the Ozhean Group's collagen-first skin architecture programme.

The Clinical Evidence: What the Published Research Shows

Re20 is the only ECM skin booster in the current category to have completed a peer-reviewed, randomised, split-face, double-blinded clinical trial. The Lee et al. 2026 study, published in the International Journal of Molecular Sciences by researchers at Yonsei University, evaluated injectable particulated hADM against a non-crosslinked hyaluronic acid control. Results demonstrated statistically significant improvements in dermal density, elasticity, and wrinkle severity in the Re20-treated side at follow-up. This remains, as of mid-2026, the only published randomised controlled trial in the ECM skin booster category.

This matters for two reasons. First, it validates the mechanism: injecting hADM into the dermis does produce measurable, objective improvements in skin structure — not just patient-reported satisfaction, but measurable changes in dermal density and elasticity on quantitative assessment. Second, it distinguishes Re20 from the wave of competing ECM skin boosters now entering the market, none of which had peer-reviewed clinical trial evidence at the time of writing. When choosing an ECM skin booster, clinical evidence for the specific product — not just the category — is one of the most important criteria.

The Four Factors That Separate One hADM Skin Booster From Another

The success of Re20 has prompted every major Korean regenerative medicine manufacturer to launch their own ECM skin booster. By mid-2026, at least four or five competing products are entering or preparing to enter the market. Not all of them are equal. Here are the four factors that should guide any patient's choice — and any clinician's product selection.

1. ECM Purity and Decellularisation Quality

The closer to 100 per cent pure ECM the manufacturer achieves — and the lower the residual lipid, DNA, and surfactant content — the lower the inflammatory burden of the injection and the more effectively the delivered matrix integrates with the patient's own tissue. Residual cellular debris and lipid membranes are recognised as foreign by the immune system, triggering local inflammation that can manifest as prolonged swelling, induration, pain, or, in rare cases, granulomatous reaction. The ISO standard for acellular biologic products requires residual DNA of less than 50 ng/mg — a threshold that Re20 meets and publishes compositional data to support. Not every ECM skin booster on the market provides equivalent transparency on purity.

2. Formulation Osmolality

Human dermal tissue is iso-osmotic, at approximately 270 to 330 mOsm/L. When an injectable is reconstituted to a hypoosmotic concentration — significantly below 270 mOsm/L, as occurs when sterile distilled water rather than physiological normal saline is used as the reconstitution vehicle — the injected solution causes water to rush into surrounding cells. The clinical result is rapid swelling, mechanical pain receptor stimulation, possible blister formation at the dermo-epidermal junction, and inflammatory cytokine release. This is one of the most common causes of the "my previous booster left bumps and unusual swelling" experience that patients report. Re20 reconstitutes to approximately 308 mOsm/L, sitting squarely in the physiological range. Not every ECM skin booster achieves this, and osmolality is one of the most under-scrutinised quality variables in this category.

3. Manufacturer Track Record

ECM skin boosters are human tissue-derived biologics — not generic pharmaceutical compounds. The manufacturer's quality systems, regulatory compliance history, and post-market surveillance discipline matter in ways that simply do not apply to HA or PN products. L&C Bio, the manufacturer of Re20, holds AATB establishment accreditation and has a clean regulatory record across its tissue product lines. When evaluating any ECM skin booster, ask specifically about the manufacturer — not just the product name — and look for AATB accreditation and a transparent post-market safety history.

4. Clinical Evidence for the Specific Product

The ECM skin booster category is scientifically sound. But clinical evidence for the category does not automatically transfer to every product within it. Different manufacturers achieve different levels of ECM purity, different particle size distributions, and different formulation characteristics — all of which influence how the product performs in vivo. The Lee et al. 2026 randomised controlled trial published in the International Journal of Molecular Sciences evaluated Re20 specifically. That evidence validates Re20; it does not validate every product in the category. Before choosing an ECM skin booster, ask whether there are peer-reviewed clinical trials for that specific product, not just the wider category.

Who Is a Good Candidate for Re20 ECM Skin Booster?

Re20 is appropriate for a wide range of patients across age groups, because ECM deterioration begins in the mid-twenties and accelerates progressively. It is particularly valuable for:

•     Patients in their thirties to fifties noticing that their skin lacks its former resilience, firmness, or hydration — despite consistent skincare and previous skin booster treatments
•     Patients who have tried multiple HA, PN, or biostimulator treatments but feel their skin still appears tired, thin, or not fully recovered
•     Patients seeking a foundational treatment before or alongside other injectables, to maximise the efficacy of subsequent skin quality treatments
•     Patients with photoaged, environmentally stressed, or lifestyle-compromised skin where the ECM has been disproportionately degraded
•     Patients who want gradual, natural-looking improvement in overall skin quality rather than single-parameter results

Re20 is not a volumising filler and does not replace structural fillers for areas of significant volume loss. It is also not the primary treatment for dynamic wrinkles (which respond better to botulinum toxin). Think of it as restoring the soil, not redesigning the landscape.

What to Expect From Re20 Treatment at Ozhean Zoey

During the Session

Re20 is delivered via a fine-gauge needle or cannula into the mid-dermis, using a multi-point injection technique across the treatment area. A topical anaesthetic is applied prior to treatment. Most patients rate discomfort at approximately 2 out of 10 — meaningfully lower than many PN injections and significantly lower than most biostimulator treatments. Sessions typically take 30 to 45 minutes for a full face treatment.

Immediately After

Small injection-site papules are normal and expected — these are the ECM particles sitting in the dermis before integration begins. They are typically not visible (but may be palpable) and resolve within two to five days. Mild redness and swelling in the treatment area is common and settles within 24 to 48 hours. Most patients return to normal activities the same day.

The Results Timeline

Initial improvement in skin texture and hydration is often apparent within one to two weeks of the first session as the ECM particles begin integrating with the patient's own matrix. Progressive improvement in firmness, elasticity, and overall skin quality continues over eight to twelve weeks as fibroblast activity normalises and new collagen is synthesised in the restored ECM environment. The typical protocol involves three sessions spaced four to six weeks apart, with maintenance every six to twelve months depending on individual ageing pace and treatment goals.

Re20 as the Foundation: Why ECM Restoration Makes Everything Else Work Effectively

One of the most consistently reported observations from dermatologists using Re20 in Korea is that it does not just improve skin quality on its own — it amplifies the results of every other treatment performed alongside or after it. This is not surprising when you understand the mechanism.

The ECM is the environment in which all skin cells operate. When that environment is restored — when collagen fibres are intact, elastin is functional, GAGs are present and correctly organised — fibroblasts resume normal activity more efficiently. HA injected into a restored ECM integrates better and remains effective for longer, because the matrix can retain it more effectively. PN signals stimulate more productive collagen synthesis because the structural cues that direct fibroblast behaviour are intact. Biostimulators produce more organised, higher-quality collagen because they are working in a healthy matrix rather than a fragmented one. Energy-based treatments — Ultherapy Prime, radiofrequency, laser — stimulate collagen in tissue that is better positioned to respond.

At Ozhean Zoey, we think of Re20 as the foundation layer in our skin quality programme. For patients who have been cycling through skin boosters without achieving the sustained improvement they are looking for, Re20 often represents the missing piece: not a replacement for their existing protocol, but the base that makes their existing protocol work at full potential.

Learn more about how Re20 combines with other treatments in our Re20 ECM Skin Booster treatment page at Ozhean Zoey.

Re20 ECM Skin Booster Price in Singapore: 2026

Re20 ECM Skin Booster in Singapore is priced per session, typically as a full-face or targeted treatment. Market pricing in Singapore generally ranges between SGD 950 and SGD 1,200 per session, with multi-session packages available at reduced per-session cost. Pricing reflects the nature of the product as a human tissue-derived biologic — more comparable to a regenerative medicine procedure than a conventional skin booster — and the clinical assessment, injection technique, and medical-grade post-care that accompany each session at Ozhean Zoey.

The three-session protocol (the standard starting programme) represents a meaningful investment in skin quality that builds over months rather than providing a single-visit improvement. Most patients find that the progressive nature of the results — gradual, cumulative, and qualitatively different from prior skin booster experiences — justifies the commitment.

Ready to Restore Your Skin's Foundation?

Re20 ECM Skin Booster is available at Ozhean Zoey Medical & Aesthetic Clinic at TripleOne Somerset, Singapore. Every Re20 treatment begins with a detailed skin assessment to determine whether ECM restoration is the right starting point — or the right addition to your existing skin programme — and to plan the appropriate protocol for your individual skin biology and goals.

Book your Re20 consultation at Ozhean Zoey Medical & Aesthetic Clinic.

Ask about our layered skin programme combining Re20 with PN skin boosters, biostimulators, and energy-based treatments for a comprehensive, structured approach to long-term skin quality.

Frequently Asked Questions About hADM and ECM Skin Boosters in Singapore

What does hADM stand for and where does it come from?

hADM stands for human acellular dermal matrix. It is derived from donated human dermal tissue that has been scientifically processed — decellularised — to remove all cells, DNA, and lipid components, leaving behind only the purified structural framework of the extracellular matrix: collagen, elastin, glycosaminoglycans, and structural proteins. The processing is performed in accredited tissue banks under strict quality frameworks. The resulting material has a well-established biocompatibility record from over three decades of use in reconstructive surgery.

Is it safe to inject human-derived material into my skin?

Yes, when properly manufactured. The decellularisation process removes all immunogenic cellular content, leaving only structural proteins that the body recognises as its own. hADM-based materials have been used safely in reconstructive and regenerative surgery for over thirty years, with an extensive published biocompatibility record. The key variable is the quality of the manufacturing process — specifically, the completeness of decellularisation. Re20 is manufactured by L&C Bio, an AATB-accredited tissue bank with a clean regulatory history, using a proprietary decellularisation platform that achieves published purity standards.

How is Re20 different from a regular HA skin booster?

A hyaluronic acid skin booster delivers water-retaining molecules that plump the dermis and improve surface hydration temporarily. Once the HA is enzymatically cleared, the skin returns towards its previous state. Re20 delivers the structural components of the ECM itself — collagen, elastin, and glycosaminoglycans — which integrate with the patient's existing matrix and trigger sustained fibroblast regenerative activity. The improvement from Re20 is progressive and builds over months, rather than peaking immediately and declining as the product clears. The two treatments are complementary rather than interchangeable.

How is Re20 different from a biostimulator like PDLLA?

Biostimulators such as PDLLA work by creating a temporary scaffold or mild inflammatory stimulus that drives new collagen production. They are highly effective for collagen regeneration but work narrowly — primarily increasing collagen quantity. They do not restore elastin, replenish GAGs in their native configuration, or reconstruct the full ECM architecture. Re20 delivers the entire ECM framework directly, addressing collagen, elastin, and glycosaminoglycans simultaneously, and creating the restored matrix environment in which biostimulator-driven collagen production becomes more organised and effective. Many patients use Re20 and biostimulators together as complementary layers of a skin programme.

What does the ECM skin booster treatment feel like?

With topical anaesthetic applied before treatment, most patients rate Re20 injections at approximately 2 out of 10 for discomfort — lower than most PN injections and significantly lower than most biostimulator treatments. You may feel mild pressure at each injection point. Small papules at the injection sites are normal and resolve within two to five days. Most patients return to normal activities the same day, with mild redness and swelling settling within 24 to 48 hours.

How many Re20 sessions will I need?

The standard starting protocol is three sessions spaced four to six weeks apart. This allows each session to build on the previous one as ECM integration progresses and fibroblast activity normalises. Many patients notice meaningful improvement after the first or second session, with the cumulative result of the three-session course typically visible at three to four months. Maintenance sessions every six to twelve months help sustain and build on results as the skin continues to age.

When will I see results from Re20?

Initial improvement in skin texture, hydration, and a general quality improvement is often perceptible within one to two weeks of the first session. Progressive improvement in firmness, elasticity, and skin resilience continues for up to three months post-session as the ECM integrates and fibroblast activity responds. The characteristic patient description is of skin that looks and feels progressively healthier and more like itself at a younger age — rather than a single dramatic change.

Can Re20 be combined with other skin boosters or treatments?

Yes — and it is often more effective when combined. Re20 restores the ECM environment, making the skin more responsive to HA (which integrates and is retained more effectively), PN (which drives more productive collagen synthesis in a healthy matrix), and biostimulators (which produce better-organised collagen in restored tissue). Re20 also pairs well with energy-based treatments: Ultherapy Prime, monopolar radiofrequency, and laser treatments all stimulate tissue remodelling that performs more effectively in a restored ECM environment. At Ozhean Zoey, Re20 is often incorporated as the foundation layer of a structured skin quality programme.

Who should not have Re20?

Re20 is contraindicated in patients with active infection or inflammation at the treatment site, patients who are pregnant or breastfeeding, and patients with known allergy to collagen or human tissue-derived products (rare, given the acellular nature of the material). Patients with autoimmune conditions or who are on immunosuppressive therapy should discuss this with the treating doctor prior to treatment. As with all injectables, a thorough pre-treatment assessment is performed at Ozhean Zoey before any Re20 session.

How do I know if the ECM skin booster I am being offered is a quality product?

Ask four questions. First: who manufactures the product, and are they AATB-accredited? Second: what is the formulation's osmolality — is it iso-osmotic to physiological dermal tissue (270 to 330 mOsm/L)? Third: what is the manufacturer's regulatory track record across their tissue product lines? Fourth: is there peer-reviewed clinical evidence for this specific product? A clinician who uses a high-quality hADM product will be able to answer all four without hesitation.

Is Re20 available in Singapore and is it HSA-approved?

Re20 is available for clinical use in Singapore at authorised clinics, including Ozhean Zoey Medical & Aesthetic Clinic at TripleOne Somerset. As a tissue-derived biologic, it is performed exclusively by registered medical practitioners. Ozhean Zoey has been performing Re20 treatments since 2025 as part of its Korean-inspired skin quality programme. All patients receive a detailed pre-treatment assessment and individualised protocol planning prior to their first session.

The Bottom Line

The extracellular matrix is the foundation of youthful skin. Not collagen alone, not hydration alone, not firmness alone — the living three-dimensional network that governs all of these functions simultaneously. Conventional skin boosters address one or two dimensions of skin ageing. ECM skin boosters address the root. They restore the soil, and in doing so, change what the entire garden can produce.

Re20 is the product that launched the ECM skin booster category in Korea and currently leads it — not because of marketing, but because of a published RCT, documented compositional purity, a physiological osmolality formulation, and a manufacturer with the quality systems to produce a consistent, safe, tissue-derived biologic. At Ozhean Zoey, we consider it the most important addition to the skin quality programme in the last five years. Not a replacement for what has come before. The foundation that makes everything else work as it should.